Contrave: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, mind-medicine combination |
MDElliottMD (talk | contribs) home-claude house-rule fix (terminology) |
||
| Line 16: | Line 16: | ||
| pregnancy = Contraindicated in pregnancy (FDA label).{{citation needed}} | | pregnancy = Contraindicated in pregnancy (FDA label).{{citation needed}} | ||
| legal = [[USLegal:Prescription only|Rx-only]] in US. '''Contraindicated''' in uncontrolled hypertension, seizure disorder, anorexia/bulimia, chronic opioid use (would precipitate withdrawal), and during/within 14 days of MAOI use. Carries '''Boxed Warning''' for suicidal thoughts and neuropsychiatric reactions (bupropion class effect)<ref name="contrave-label" /> | | legal = [[USLegal:Prescription only|Rx-only]] in US. '''Contraindicated''' in uncontrolled hypertension, seizure disorder, anorexia/bulimia, chronic opioid use (would precipitate withdrawal), and during/within 14 days of MAOI use. Carries '''Boxed Warning''' for suicidal thoughts and neuropsychiatric reactions (bupropion class effect)<ref name="contrave-label" /> | ||
| mechanism = <vote slug="contrave-mech-claim">Bupropion inhibits norepinephrine and dopamine reuptake, activating POMC neurons in the hypothalamus to release α-MSH (suppressing appetite) and β-endorphin (which would normally feed back to inhibit POMC). Naltrexone blocks the β-endorphin autoinhibition, sustaining the appetite-suppressing POMC activity. The combination achieves greater weight loss than either component alone.</vote> Modest absolute weight loss (~5% from baseline at 1 year) versus placebo. | | mechanism = <vote slug="contrave-mech-claim">Bupropion inhibits norepinephrine and dopamine reuptake, activating POMC neurons in the hypothalamus to release α-MSH (suppressing appetite) and β-endorphin (which would normally feed back to inhibit POMC). Naltrexone blocks the β-endorphin autoinhibition, sustaining the appetite-suppressing POMC activity. The combination achieves greater weight loss than either component alone.</vote> Modest absolute weight loss (~5% from baseline at 1 year) versus placebo. Interaction profile includes CYP2D6 inhibition (bupropion), so dose-adjustment for tricyclic antidepressants, β-blockers metabolized by 2D6, and certain neuroleptics is warranted<ref name="contrave-label" />. | ||
}} | }} | ||
== References == | == References == | ||
<references /> | <references /> | ||